lncRNA MIR4435‑2HG promotes the progression of liver cancer by upregulating B3GNT5 expression

Zhu,Yungang; Li,Baoguo; Xu,Guoping; Han,Changrui; Xing,Gang

doi:10.3892/mmr.2021.12554

lncRNA MIR4435‑2HG promotes the progression of liver cancer by upregulating B3GNT5 expression

Authors:
- Yungang Zhu
- Baoguo Li
- Guoping Xu
- Changrui Han
- Gang Xing
View Affiliations

Affiliations: Radiology Department, Tianjin Teda Hospital, Tianjin 300457, P.R. China, Department of Interventional Treatment, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China, Medical Imaging Department, Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China
Published online on: December 2, 2021 https://doi.org/10.3892/mmr.2021.12554
Article Number: 38
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several studies have indicated that dysregulation of long non‑coding RNAs (lncRNAs) participates in the initiation and progression of cancer. The lncRNA MIR4435‑2HG was previously reported to act as an oncogene in human cancer, including liver cancer. However, its role in the pathogenesis in liver cancer is largely unclear. The present study aimed to reveal the molecular mechanism by which MIR4435‑2HG regulates liver cancer. The expression levels of MIR4435‑2HG in liver cancer and adjacent normal tissues were analyzed using The Cancer Genome Atlas database. MIR4435‑2HG expression was validated by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) in cancer cells in vitro. The target genes of MIR4435‑2HG were predicted using bioinformatics analysis. Interactions between miR‑136‑5p, MIR4435‑2HG and B3GNT5 were detected using luciferase reporter assays, and their effects on cell viability, migration and invasion were assessed using Cell Counting Kit‑8, wound healing and Transwell assays. The effects of miR‑136‑5p and MIR4435‑2HG on B3GNT5 expression were confirmed by western blot analysis. The results revealed that MIR4435‑2HG expression was upregulated in primary liver cancer and liver cancer cell lines, and was positively associated with advanced tumor stage, metastasis and poor prognosis in patients with liver cancer. Knockdown of MIR4435‑2HG significantly inhibited the proliferation, migration and invasion of liver cancer cells. Furthermore, miR‑136‑5p was determined to be a direct target of MIR4435‑2HG and suppressed MIR4435‑2HG expression by binding with the seed region of the 3'‑UTR of MIR4435‑2HG in liver cancer cells. Functional studies showed that the inhibitory effects of MIR4435‑2HG knockdown on cell proliferation, migration and invasion were significantly rescued by inhibiting miR‑136‑5p. Furthermore, the target gene, B3GNT5, of miR‑136‑5p was confirmed by bioinformatics analysis and RT‑qPCR. In addition, B3GNT5 expression was regulated by the MIR4435‑2HG/miR‑136‑5p axis. In conclusion, the present study indicated that MIR4435‑2HG facilitated the progression of liver cancer via the MIR4435‑2HG/miR‑136‑5p/B3GNT5 axis, which demonstrated that MIR4435‑2HG may be a potential biomarker for the prognosis and treatment of liver cancer.

View Figures

View References

1	Satriano L, Lewinska M, Rodrigues PM, Banales JM and Andersen JB: Metabolic rearrangements in primary liver cancers: Cause and consequences. Nat Rev Gastroenterol Hepatol. 16:748–766. 2019. View Article : Google Scholar : PubMed/NCBI
2	Anwanwan D, Singh SK, Singh S, Saikam V and Singh R: Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 1873:1883142020. View Article : Google Scholar : PubMed/NCBI
3	Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM and Shoreibah MG: Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol. 25:1550–1559. 2019. View Article : Google Scholar : PubMed/NCBI
4	Aldrighetti L, Pulitano C, Catena M, Arru M, Guzzetti E, Halliday J and Ferla G: Liver resection with portal vein thrombectomy for hepatocellular carcinoma with vascular invasion. Ann Surg Oncol. 16:12542009. View Article : Google Scholar : PubMed/NCBI
5	Li J, Li Z, Zheng W, Li X, Wang Z, Cui Y and Jiang X: LncRNA-ATB: An indispensable cancer-related long noncoding RNA. Cell Prolif. 50:e123812017. View Article : Google Scholar : PubMed/NCBI
6	Ulitsky I and Bartel DP: lincRNAs: Genomics, evolution, and mechanisms. Cell. 154:26–46. 2013. View Article : Google Scholar : PubMed/NCBI
7	Shi X, Sun M, Liu H, Yao Y and Song Y: Long non-coding RNAs: A new frontier in the study of human diseases. Cancer Lett. 339:159–166. 2013. View Article : Google Scholar : PubMed/NCBI
8	Chen C, Zheng H, Luo Y, Kong Y, An M, Li Y, He W, Gao B, Zhao Y, Huang H, et al: SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer. J Clin Invest. 131:e1464312021. View Article : Google Scholar : PubMed/NCBI
9	Qin Y, Hou Y, Liu S, Zhu P, Wan X, Zhao M, Peng M, Zeng H, Li Q, Jin T, et al: A novel long non-coding RNA lnc030 maintains breast cancer stem cell stemness by stabilizing SQLE mRNA and increasing cholesterol synthesis. Adv Sci (Weinh). 8:20022322020. View Article : Google Scholar : PubMed/NCBI
10	Zhang F, Wang H, Yu J, Yao X, Yang S, Li W, Xu L and Zhao L: LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM. Mol Cancer. 20:62021. View Article : Google Scholar : PubMed/NCBI
11	Dong X, Yang Z, Yang H, Li D and Qiu X: Long non-coding RNA MIR4435-2HG promotes colorectal cancer proliferation and metastasis through miR-206/YAP1 axis. Front Oncol. 10:1602020. View Article : Google Scholar : PubMed/NCBI
12	Wang H, Wu M, Lu Y, He K, Cai X, Yu X, Lu J and Teng L: LncRNA MIR4435-2HG targets desmoplakin and promotes growth and metastasis of gastric cancer by activating Wnt/β-catenin signaling. Aging (Albany NY). 11:6657–6673. 2019. View Article : Google Scholar : PubMed/NCBI
13	Yang M, He X, Huang X, Wang J, He Y and Wei L: LncRNA MIR4435-2HG-mediated upregulation of TGF-β1 promotes migration and proliferation of nonsmall cell lung cancer cells. Environ Toxicol. 35:582–590. 2020. View Article : Google Scholar : PubMed/NCBI
14	Shen X, Ding Y, Lu F, Yuan H and Luan W: Long noncoding RNA MIR4435-2HG promotes hepatocellular carcinoma proliferation and metastasis through the miR-22-3p/YWHAZ axis. Am J Transl Res. 12:6381–6394. 2020.PubMed/NCBI
15	Kong Q, Liang C, Jin Y, Pan Y, Tong D, Kong Q and Zhou J: The lncRNA MIR4435-2HG is upregulated in hepatocellular carcinoma and promotes cancer cell proliferation by upregulating miRNA-487a. Cell Mol Biol Lett. 24:262019. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Wang S, Zhang X, Li Z, Wang W, Li B, Huang X, Sun G, Xu J, Li Q, Xu Z, et al: Circular RNA profile identifies circOSBPL10 as an oncogenic factor and prognostic marker in gastric cancer. Oncogene. 38:6985–7001. 2019. View Article : Google Scholar : PubMed/NCBI
18	Han C, Fu Y, Zeng N, Yin J and Li Q: LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis. Aging (Albany NY). 12:3594–3616. 2020. View Article : Google Scholar : PubMed/NCBI
19	Kang W, Wang Q, Dai Y, Wang H, Wang M, Wang J, Zhang D, Sun P, Qi T, Jin X and Cui Z: Hypomethylation of PlncRNA-1 promoter enhances bladder cancer progression through the miR-136-5p/Smad3 axis. Cell Death Dis. 11:10382020. View Article : Google Scholar : PubMed/NCBI
20	Wang Z, Huang C, Zhang A, Lu C and Liu L: Overexpression of circRNA_100290 promotes the progression of laryngeal squamous cell carcinoma through the miR-136-5p/RAP2C axis. Biomed Pharmacother. 125:1098742020. View Article : Google Scholar : PubMed/NCBI
21	Xu N, Wu YP, Ke ZB, Liang YC, Cai H, Su WT, Tao X, Chen SH, Zheng QS, Wei Y and Xue XY: Identification of key DNA methylation-driven genes in prostate adenocarcinoma: An integrative analysis of TCGA methylation data. J Transl Med. 17:3112019. View Article : Google Scholar : PubMed/NCBI
22	Kresovich JK, Joyce BT, Gao T, Zheng Y, Zhang Z, Achenbach CJ, Murphy RL, Just AC, Shen J, Yang H, et al: Promoter methylation of PGC1A and PGC1B predicts cancer incidence in a veteran cohort. Epigenomics. 10:733–743. 2018. View Article : Google Scholar : PubMed/NCBI
23	Weisenberger DJ, Liang G and Lenz HJ: DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies. Oncogene. 37:566–577. 2018. View Article : Google Scholar : PubMed/NCBI
24	Kwok CT, Marshall AD, Rasko JE and Wong JJ: Genetic alterations of m ⁶ A regulators predict poorer survival in acute myeloid leukemia. J Hematol Oncol. 10:392017. View Article : Google Scholar : PubMed/NCBI
25	Fernandes T, Barretti DL, Phillips MI and Menezes Oliveira E: Exercise training prevents obesity-associated disorders: Role of miRNA-208a and MED13. Mol Cell Endocrinol. 476:148–154. 2018. View Article : Google Scholar : PubMed/NCBI
26	Correia de Sousa M, Gjorgjieva M, Dolicka D, Sobolewski C and Foti M: Deciphering miRNAs' action through miRNA editing. Int J Mol Sci. 20:62492019. View Article : Google Scholar : PubMed/NCBI
27	Klingenberg M, Matsuda A, Diederichs S and Patel T: Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. J Hepatol. 67:603–618. 2017. View Article : Google Scholar : PubMed/NCBI
28	Wang B, Tang D, Zhang Z and Wang Z: Identification of aberrantly expressed lncRNA and the associated TF-mRNA network in hepatocellular carcinoma. J Cell Biochem. 121:1491–1503. 2020. View Article : Google Scholar : PubMed/NCBI
29	Su R, Cao S, Ma J, Liu Y, Liu X, Zheng J, Chen J, Liu L, Cai H, Li Z, et al: Knockdown of SOX2OT inhibits the malignant biological behaviors of glioblastoma stem cells via up-regulating the expression of miR-194-5p and miR-122. Mol Cancer. 16:1712017. View Article : Google Scholar : PubMed/NCBI
30	Wang K, Jin W, Song Y and Fei X: LncRNA RP11-436H11.5, functioning as a competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335-5p and promotes proliferation and invasion in renal cell carcinoma. Mol Cancer. 16:1662017. View Article : Google Scholar : PubMed/NCBI
31	Lu S, Zhou J, Sun Y, Li N, Miao M, Jiao B and Chen H: The noncoding RNA HOXD-AS1 is a critical regulator of the metastasis and apoptosis phenotype in human hepatocellular carcinoma. Mol Cancer. 16:1252017. View Article : Google Scholar : PubMed/NCBI
32	Dong H, Jian P, Yu M and Wang L: Silencing of long noncoding RNA LEF1-AS1 prevents the progression of hepatocellular carcinoma via the crosstalk with microRNA-136-5p/WNK1. J Cell Physiol. 235:6548–6562. 2020. View Article : Google Scholar : PubMed/NCBI
33	Zhang W, Shi J, Cheng C and Wang H: CircTIMELESS regulates the proliferation and invasion of lung squamous cell carcinoma cells via the miR-136-5p/ROCK1 axis. J Cell Physiol. 235:5962–5971. 2020. View Article : Google Scholar : PubMed/NCBI
34	Zhu L, Liu Y, Chen Q, Yu G, Chen J, Chen K, Yang N, Zeng T, Yan S, Huang A and Tang H: Long-noncoding RNA colorectal neoplasia differentially expressed gene as a potential target to upregulate the expression of IRX5 by miR-136-5P to promote oncogenic properties in hepatocellular carcinoma. Cell Physiol Biochem. 50:2229–2248. 2018. View Article : Google Scholar : PubMed/NCBI
35	Jeong HY, Park SY, Kim HJ, Moon S, Lee S, Lee SH and Kim SH: B3GNT5 is a novel marker correlated with stem-like phenotype and poor clinical outcome in human gliomas. CNS Neurosci Ther. 26:1147–1154. 2020. View Article : Google Scholar : PubMed/NCBI